H.C. Wainwright analyst Emily Bodnar raised the firm’s price target on Gracell to $13 from $12 and keeps a Buy rating on the shares post the Q2 report. The company initiated screening patients to be enrolled in the GC012F Phase 1b study and the first clinical site has been activated, the analyst tells investors in a research note. The firm estimates Gracell has sufficient cash and equivalents to fund operations into 2026.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on GRCL:
- Gracell Biotechnologies Reports Second Quarter 2023 Unaudited Financial Results and Provides Corporate Update
- Gracell reports Q2 EPS (RMB 43c) vs (RMB 43c) last year
- GRCL Upcoming Earnings Report: What to Expect?
- Gracell announces $150M private placement
- Gracell Biotechnologies to Report Second Quarter 2023 Financials on Monday, August 14, 2023
